In patients with light chain amyloidosis and cardiac involvement, treatment with D-VCd resulted in higher rates of cardiac response, with possible improvement in fatigue-related variables. Read More ›

Preliminary findings suggest that diflunisal may be a cost-effective alternative for patients with transthyretin amyloid cardiomyopathy who may not be able to afford tafamidis. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: